Tags

Type your tag names separated by a space and hit enter

Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Eur J Clin Microbiol Infect Dis. 2021 Aug; 40(8):1755-1759.EJ

Abstract

The spread of multidrug-resistant (MDR), metallo-β-lactamase (MBL)-producing Klebsiella pneumoniae represents a major therapeutic challenge. The newly introduced β-lactam-β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (M/V), and imipenem/relebactam (I/R) are inactive against MBLs. The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method. Synergy was defined as a fractional inhibitory concentration index ≤0.5. All isolates were resistant to ATM, CAZ/AVI, and I/R and 38/40 (95%) were resistant to M/V. Synergy was observed in 97.5% in the combinations CAZ/AVI-ATM, and I/R-ATM and in 72.5% in the combination M/V-ATM. Further clinical studies are required to confirm the efficacy of these antimicrobial combinations.

Authors+Show Affiliations

Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece. sofiamaraki@yahoo.gr.University of Crete Medical School, Heraklion, Crete, Greece.Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece.Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece.Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece.Laboratory of Clinical Microbiology and Molecular Microbiology, School of Medicine, University of Crete, Crete, Greece.Laboratory of Clinical Microbiology and Molecular Microbiology, School of Medicine, University of Crete, Crete, Greece.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33595756

Citation

Maraki, Sofia, et al. "Ceftazidime-avibactam, Meropenen-vaborbactam, and Imipenem-relebactam in Combination With Aztreonam Against Multidrug-resistant, Metallo-β-lactamase-producing Klebsiella Pneumoniae." European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, vol. 40, no. 8, 2021, pp. 1755-1759.
Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755-1759.
Maraki, S., Mavromanolaki, V. E., Moraitis, P., Stafylaki, D., Kasimati, A., Magkafouraki, E., & Scoulica, E. (2021). Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 40(8), 1755-1759. https://doi.org/10.1007/s10096-021-04197-3
Maraki S, et al. Ceftazidime-avibactam, Meropenen-vaborbactam, and Imipenem-relebactam in Combination With Aztreonam Against Multidrug-resistant, Metallo-β-lactamase-producing Klebsiella Pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755-1759. PubMed PMID: 33595756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. AU - Maraki,Sofia, AU - Mavromanolaki,Viktoria Eirini, AU - Moraitis,Panagiotis, AU - Stafylaki,Dimitra, AU - Kasimati,Anna, AU - Magkafouraki,Eleni, AU - Scoulica,Effie, Y1 - 2021/02/17/ PY - 2020/12/14/received PY - 2021/02/11/accepted PY - 2021/2/18/pubmed PY - 2021/8/31/medline PY - 2021/2/17/entrez KW - Aztreonam KW - Carbapenem resistance KW - Ceftazidime/avibactam KW - Imipenem/relebactam KW - Klebsiella pneumoniae KW - MBL KW - Meropenem/vaborbactam KW - Synergy SP - 1755 EP - 1759 JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JO - Eur J Clin Microbiol Infect Dis VL - 40 IS - 8 N2 - The spread of multidrug-resistant (MDR), metallo-β-lactamase (MBL)-producing Klebsiella pneumoniae represents a major therapeutic challenge. The newly introduced β-lactam-β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (M/V), and imipenem/relebactam (I/R) are inactive against MBLs. The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method. Synergy was defined as a fractional inhibitory concentration index ≤0.5. All isolates were resistant to ATM, CAZ/AVI, and I/R and 38/40 (95%) were resistant to M/V. Synergy was observed in 97.5% in the combinations CAZ/AVI-ATM, and I/R-ATM and in 72.5% in the combination M/V-ATM. Further clinical studies are required to confirm the efficacy of these antimicrobial combinations. SN - 1435-4373 UR - https://www.unboundmedicine.com/medline/citation/33595756/Ceftazidime_avibactam_meropenen_vaborbactam_and_imipenem_relebactam_in_combination_with_aztreonam_against_multidrug_resistant_metallo_β_lactamase_producing_Klebsiella_pneumoniae_ L2 - https://dx.doi.org/10.1007/s10096-021-04197-3 DB - PRIME DP - Unbound Medicine ER -